USFDA issues 9 observations for Canada contract manufacturing facility: Jubilant Pharmova
Noida: Jubilant Pharmova Limited has announced that the United States Food and Drug Administration (USFDA) has concluded an audit of Jubilant HollisterStier General Partnership (“JHSGP”)’s contract manufacturing facility located in Montreal, Canada, with 9 observations.
"JHSGP will submit an action plan on the observations," the company stated in a BSE filing.
JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly owned subsidiary of the Company.
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses.
Read also: Jubilant HollisterStier unveils high speed Isolator based Line at Spokane facility in US
Next Story